research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
Search
for
Sort by
Research
450-480 / 1000+ results 
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
JAK inhibitors may help improve symptoms in adults with APECED.
research Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors
Stopping gefitinib improved scalp condition in a woman with lung cancer.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
research ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A
Biochanin A from soy is a promising and safe candidate for treating hair loss.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Cedrol from Platycladus orientalis (L.) Franco regulates M1/M2 polarization of macrophages and promotes hair regeneration
Cedrol promotes hair growth better than baricitinib by regulating immune cells.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Long non-coding RNA AL136131.3 inhibits hair growth through mediating PPARγ in androgenetic alopecia
A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research 1394 Long non-coding RNA AL136131.3 inhibits hair growth through mediating glycolysis in androgenetic alopecia
AL136131.3 slows hair growth by affecting energy processes in hair loss.
research Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research An unusual terminal hair growth on the nose tip associated with gefitinib therapy
Gefitinib therapy can cause unusual hair growth on the nose.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research From joint pains to hair gains: baricitinib’s double duty for rheumatoid arthritis and alopecia areata
Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.